Rocket Pharmaceuticals Stock Fundamentals
| RCKT Stock | USD 8.43 0.11 1.32% |
Rocket Pharmaceuticals fundamentals help investors to digest information that contributes to Rocket Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Rocket Stock. The fundamental analysis module provides a way to measure Rocket Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Rocket Pharmaceuticals stock.
At this time, Rocket Pharmaceuticals' Non Operating Income Net Other is comparatively stable compared to the past year. Net Interest Income is likely to gain to about 15.2 M in 2025, despite the fact that EBITDA is likely to grow to (259.5 M).
Rocket | Select Account or Indicator |
Rocket Pharmaceuticals Company Return On Equity Analysis
Rocket Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Rocket Pharmaceuticals Return On Equity | -0.54 |
Most of Rocket Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Rocket Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Rocket Total Stockholder Equity
Total Stockholder Equity |
|
At this time, Rocket Pharmaceuticals' Total Stockholder Equity is comparatively stable compared to the past year.
Based on the latest financial disclosure, Rocket Pharmaceuticals has a Return On Equity of -0.5414. This is 97.74% lower than that of the Biotechnology sector and 98.52% lower than that of the Health Care industry. The return on equity for all United States stocks is 74.65% higher than that of the company.
Rocket Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Rocket Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Rocket Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Rocket Pharmaceuticals competition to find correlations between indicators driving Rocket Pharmaceuticals's intrinsic value. More Info.Rocket Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Rocket Pharmaceuticals' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Rocket Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Rocket Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rocket Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Rocket Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Rocket Pharmaceuticals by comparing valuation metrics of similar companies.Rocket Pharmaceuticals is currently under evaluation in return on equity category among its peers.
Rocket Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Rocket Pharmaceuticals from analyzing Rocket Pharmaceuticals' financial statements. These drivers represent accounts that assess Rocket Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Rocket Pharmaceuticals' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 3.0B | 1.4B | 1.3B | 2.5B | 1.2B | 928.1M | |
| Enterprise Value | 2.8B | 1.2B | 1.2B | 2.5B | 1.1B | 845.7M |
Rocket Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Rocket Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Rocket Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Rocket Fundamentals
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.31 | ||||
| Current Valuation | 555.25 M | ||||
| Shares Outstanding | 106.63 M | ||||
| Shares Owned By Insiders | 3.01 % | ||||
| Shares Owned By Institutions | 96.99 % | ||||
| Number Of Shares Shorted | 11.24 M | ||||
| Price To Book | 1.95 X | ||||
| EBITDA | (273.2 M) | ||||
| Net Income | (258.75 M) | ||||
| Cash And Equivalents | 321.37 M | ||||
| Cash Per Share | 4.87 X | ||||
| Total Debt | 25.5 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 13.41 X | ||||
| Book Value Per Share | 4.35 X | ||||
| Cash Flow From Operations | (209.72 M) | ||||
| Short Ratio | 8.52 X | ||||
| Earnings Per Share | (2.73) X | ||||
| Price To Earnings To Growth | 0.03 X | ||||
| Target Price | 41.53 | ||||
| Number Of Employees | 299 | ||||
| Beta | 1.02 | ||||
| Market Capitalization | 887.16 M | ||||
| Total Asset | 527.7 M | ||||
| Retained Earnings | (1.22 B) | ||||
| Working Capital | 337.5 M | ||||
| Net Asset | 527.7 M |
About Rocket Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rocket Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rocket Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rocket Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | -11.5 M | -10.9 M | |
| Cost Of Revenue | 8.2 M | 8.6 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Rocket Stock Analysis
When running Rocket Pharmaceuticals' price analysis, check to measure Rocket Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rocket Pharmaceuticals is operating at the current time. Most of Rocket Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rocket Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rocket Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rocket Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.